Savara Inc.(SVRA)

Biotechnology · Yardley, PA

$4.65-0.13 (-2.72%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T21:38:38.907Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:38:38.907Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 952,910,550
TTM free cash flow · period ending 2026-06-30: -110,660,000

FMP input reference: 91899883c476d55b2433093e583c87952940339a9b77bc55d8a3dd78c9ec7759

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

SVRA Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

SVRA Competitors' Price/FCF Ratio

SVRA

Savara Inc.

Current

Market Cap

$952.91M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AKTS

Aktis Oncology, Inc.

vs SVRA

Market Cap

$953.81M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KURA

Kura Oncology, Inc.

vs SVRA

Market Cap

$934.79M

Price/FCF Ratio

N/A

TTM Avg

6.84

3Y Avg

6.83

5Y Avg

6.83

PCRX

Pacira BioSciences, Inc.

vs SVRA

Market Cap

$973.93M

Price/FCF Ratio

5.43

TTM Avg

7.51

3Y Avg

7.85

5Y Avg

14.47

SPTX

Seaport Therapeutics, Inc. Common Stock

vs SVRA

Market Cap

$929.83M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LTGO

Latigo Biotherapeutics Inc.

vs SVRA

Market Cap

$978.09M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGTX

MeiraGTx Holdings plc

vs SVRA

Market Cap

$981.66M

Price/FCF Ratio

N/A

TTM Avg

31.06

3Y Avg

31.06

5Y Avg

31.06

CBLL

CeriBell, Inc.

vs SVRA

Market Cap

$923.53M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LBRX

LB Pharmaceuticals Inc Common Stock

vs SVRA

Market Cap

$982.46M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MLTX

MoonLake Immunotherapeutics

vs SVRA

Market Cap

$921.06M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Savara Inc. (SVRA)	$952.91M	N/A	N/A	N/A	N/A
Aktis Oncology, Inc. (AKTS)vs ›	$953.81M	N/A	N/A	N/A	N/A
Kura Oncology, Inc. (KURA)vs ›	$934.79M	N/A	6.84	6.83	6.83
Pacira BioSciences, Inc. (PCRX)vs ›	$973.93M	5.43	7.51	7.85	14.47
Seaport Therapeutics, Inc. Common Stock (SPTX)vs ›	$929.83M	N/A	N/A	N/A	N/A
Latigo Biotherapeutics Inc. (LTGO)vs ›	$978.09M	N/A	N/A	N/A	N/A
MeiraGTx Holdings plc (MGTX)vs ›	$981.66M	N/A	31.06	31.06	31.06
CeriBell, Inc. (CBLL)vs ›	$923.53M	N/A	N/A	N/A	N/A
LB Pharmaceuticals Inc Common Stock (LBRX)vs ›	$982.46M	N/A	N/A	N/A	N/A
MoonLake Immunotherapeutics (MLTX)vs ›	$921.06M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/FCF Ratio: N/A

SVRA Price/FCF Ratio Metrics

SVRA Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Related Metrics